Compositions for oral administration of zoledronic acid or related compounds for treating ankylosing spondylitis
View Patent ↗Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailabilty of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
1. A method of treating ankylosing spondylitis, comprising orally administering zoledronic acid in the disodium salt form to a mammal in need thereof, wherein the zoledronic acid in the disodium salt form is administered in an amount and frequency that results in an AUC of zoledronic acid, over a four week period, that is about 100 ng·h/mL to about 2000 ng·h/mL.
2. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered once a month, or less frequently.
3. The method of claim 2 , wherein the mammal experiences pain relief at least 3 weeks after a dose of zoledronic acid in the disodium salt form is administered.
4. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered weekly.
5. The method of claim 4 , wherein the mammal experiences pain relief at least 48 hours after a dose of zoledronic acid in the disodium salt form is administered.
6. The method of claim 1 , wherein the zoledronic acid is administered in the disodium salt form 2 to 5 times in a month.
7. The method of claim 6 , wherein the mammal experiences pain relief at least 12 hours after a dose of zoledronic acid in the disodium salt form is administered.
8. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered daily.
9. The method of claim 8 , wherein the mammal experiences pain relief at least 12 hours after a dose of zoledronic acid in the disodium salt form is administered.
10. The method of claim 1 , wherein the mammal is a human being.
11. The method of claim 10 , wherein the human being has an age of at least 10 years.
12. The method of claim 10 , wherein human being to which the zoledronic acid in the disodium salt form is administered does not eat food or drink beverage for at least 1 hour before the zoledronic acid in the disodium salt form is administered.
13. The method of claim 10 , wherein the human being has suffered from ankylosing spondylitis for at least 6 months.
14. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in an amount and frequency that results in an AUC of zoledronic acid, over a one week period, that is about 20 ng·h/mL to about 500 ng·h/mL.
15. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a solid dosage form having a hardness of about 5 kPa to about 20 kPa.
16. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a solid dosage form that contains at least about 50% (w/w) of zoledronic acid in the disodium salt form.
17. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered daily, and a daily dose contains an amount of zoledronic acid in the disodium salt form that results in an AUC of zoledronic acid that is about 4 ng·h/mL to about 30 ng·h/mL.
18. The method of claim 1 , wherein the zoledronic acid in the disodium salt form is administered in a manner so that the bioavailability of zoledronic acid is 1.5% to 3% in the mammal being treated.
19. The method of claim 2 , wherein zoledronic acid in the disodium salt form is administered once a month for only 3 months.
20. The method of claim 1 , wherein the mammal receives about 40 mg to about 1000 mg of zoledronic acid in the disodium salt form per month.
21. The method of claim 1 , wherein the mammal receives about 40 mg to about 300 mg of zoledronic acid in the disodium salt form per month.